


INCREASING THE QUALITY OF LIFE

PAD (peripheral arterial occlusive disease) causes a reduction in arterial perfusion at the extremities. As a chronic vascular disease, it has a huge impact on health, with increasing exercise-dependent pain and walking distance reduction (intermittent claudication) up to and including critical ischaemia.

This is where STIVAX neurostimulation therapy may achieve surprising success: modulations in the brain stem caused by intermittent continuous stimulation of the vagus nerve in the triangular fossa result in improved perfusion of the extremities - without active substances and minimal invasive.

The aim of treatment is to slow the progress of the disease, prevent amputations and facilitate greater freedom of movement and thus a better quality of life.



ARTERIOLES

The brain stem uses neuro transmitters to influence the intensity and rhythm of arteriole movements.

VAGUS NERVE

Stimulation of the afferent branch of the vagus nerve causes the brain stem to achieve improved microcirculation in the extremities via arterioles.

INNOVATIVE THERAPY

It goes without saying that tried and tested methods are the best therapy in medicine, with innovative, clinically-tested approaches providing a valuable complement. This is the basis for STIVAX therapy.

STIVAX NEUROSTIMULATION THERAPY

Conservative treatment for PAD patients extends walking distances to a multiple of original values and supports wound healing.


STIVAX STIMULATOR

Integral component of STIVAX therapy. The mechanism of action is based on stimulation of the vagus nerve.

HOW TO GET BETTER

A clinical trial by senior consultant Dr Thomas Payrits on vagus stimulation in PAD patients supports the effectiveness of STIVAX stimulation therapy: in addition to good data quality and a high level of patient compliance, study results show a significant rise in the transcutaneous partial pressure of oxygen between the initial examination and the final one.

The other parameters for efficacy and quality of life in the form of ABI SF-36 health surveys and the walking distance test also have similar results and thus confirm therapeutic success as an effective measure for improving the symptoms of PAD.



Payrits et al. 2015, awaiting publication

SIMPLY CONVINCING

- Minimally-invasive administration
- Effective improvement in the quality of life of PAD patients
- Significant reduction in treatment complexity
- Potential reduction in long-term treatment costs
- Easy application
- Protected from splashes
- Prescribed by a physician
- No active substances
- Enhancement of patient compliance

BIEGLER GMBH
Austria/Europe, 3001 Mauerbach, Allhangstrasse 18a, Tel. +43 1 979 21 05, office@biegler.com,
www.biegler.com

BIEGLER
MEDIZIN ELEKTRONIK



STIVAX
STIMULATOR

PAD TREATMENT WITH A SUSTAINED EFFECT